Ivan Spicka
Overview
Explore the profile of Ivan Spicka including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
119
Citations
5339
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Richardson P, Perrot A, San-Miguel J, Beksac M, Spicka I, Leleu X, et al.
Future Oncol
. 2025 Jan;
21(6):653-663.
PMID: 39851267
No abstract available.
2.
Dimopoulos M, Voorhees P, Schjesvold F, Cohen Y, Hungria V, Sandhu I, et al.
N Engl J Med
. 2024 Dec;
PMID: 39652675
Background: Daratumumab, an anti-CD38 monoclonal antibody, has been approved for the treatment of multiple myeloma. Data are needed regarding the use of daratumumab for high-risk smoldering multiple myeloma, a precursor...
3.
Richardson P, Perrot A, Mikhael J, Martin T, Beksac M, Spicka I, et al.
Blood Cancer J
. 2024 Nov;
14(1):209.
PMID: 39609425
The International Staging System for multiple myeloma recently underwent a second revision (R2-ISS) to include gain/amplification of 1q21 and account for the additive prognostic significance of multiple high-risk features. The...
4.
Yong K, Martin T, Dimopoulos M, Mikhael J, Capra M, Facon T, et al.
Lancet Haematol
. 2024 Jul;
11(10):e741-e750.
PMID: 39067465
Background: Isatuximab is an anti-CD38 monoclonal antibody approved for the treatment of relapsed or refractory multiple myeloma. Previous analyses of the IKEMA trial showed prolonged progression-free survival in patients with...
5.
Dimopoulos M, Coriu D, Delimpasi S, Spicka I, Upchurch T, Fang B, et al.
Blood Adv
. 2024 Jul;
8(19):5012-5021.
PMID: 39024542
Twice-weekly carfilzomib (27 mg/m2) plus lenalidomide and dexamethasone (KRd27) is a standard of care in relapsed/refractory multiple myeloma (RRMM). Once-weekly carfilzomib regimens have shown clinical benefits with improved patient convenience....
6.
Kapoor P, Nathwani N, Jelinek T, Pour L, Perrot A, Dimopoulos M, et al.
Eur J Haematol
. 2024 Jul;
113(5):593-605.
PMID: 38993150
Objectives: Cluster of differentiation 38 (CD38) is a key target on multiple myeloma (MM) cells. This multi-centre, Phase 1, single-agent study (NCT04000282) investigated SAR442085, a novel fragment crystallisable (Fc)-modified anti-CD38...
7.
Oriol A, Hajek R, Spicka I, Sandhu I, Cohen Y, Gatt M, et al.
Clin Lymphoma Myeloma Leuk
. 2024 Jun;
24(10):703-714.
PMID: 38849283
Background: Preclinical studies suggest that combining nivolumab, a programmed death-1 (PD-1) immune checkpoint inhibitor, with pomalidomide/dexamethasone (Pd) with or without elotuzumab, an antisignaling lymphocytic activation molecule F7 monoclonal antibody, may...
8.
Facon T, Dimopoulos M, Leleu X, Beksac M, Pour L, Hajek R, et al.
N Engl J Med
. 2024 Jun;
391(17):1597-1609.
PMID: 38832972
Background: Bortezomib, lenalidomide, and dexamethasone (VRd) is a preferred first-line treatment option for patients with newly diagnosed multiple myeloma. Whether the addition of the anti-CD38 monoclonal antibody isatuximab to the...
9.
Dimopoulos M, Beksac M, Pour L, Delimpasi S, Vorobyev V, Quach H, et al.
N Engl J Med
. 2024 Jun;
391(5):408-421.
PMID: 38828951
Background: Triplet or quadruplet therapies incorporating proteasome inhibitors, immunomodulators, and anti-CD38 antibodies have led to prolonged survival among patients with newly diagnosed multiple myeloma; however, most patients have a relapse....
10.
Schjesvold F, Ludwig H, Delimpasi S, Robak P, Coriu D, Tomczak W, et al.
Haematologica
. 2024 Mar;
109(7):2331-2336.
PMID: 38426292
No abstract available.